Read our new manuscript on OpSCF published in Nature Mucosal Immunology (2019) in the Newsroom.
The full article can be accessed on PubMed or the NMI Journal website.
Our mission is to develop human therapeutics to treat serious diseases caused by chronic inflammation including glomerulonephritis and chronic kidney disease, pulmonary fibrosis, scleroderma and severe asthma.
Tens of millions of people suffer from chronic inflammatory diseases that may result in fibrosis. Fibrosis is the replacement of normal tissue with scar-like fibrous tissue. Fibrosis is the cause of severe organ dysfunction and eventually death. In laboratory studies, OpSCF interrupts chronic inflammation, returning the environment to normal, preventing fibrosis and allowing tissues to heal.
patient no.2_home image_1.2019